CD8A and myeloid sarcoma: Here we show the selective reduction of CD8+ MAIT cells, characterized by high surface levels of CD161 and the expression of TCR invariant alpha chain Vα7.2 (14), in blood cells of patients affected by primary progressive MS and no other MS courses or another neurological disorder, such as ALS.